Each CureMatch analysis is unique, it depends on the type of NGS test results available and the biomarkers that are detected. CureMatch focuses on the personalized molecular matching of somatic NGS biomarkers of clinical relevance, as well as other possible data sources.
Identify the most effective cancer drugs and avoid ineffective ones. CureMatch helps identify and stay clear of ineffective treatments, so patients are treated earlier, thereby increasing their chance of a better outcome. Curbing wasteful spending on ineffective, low-clinical-value treatments in favor of more effective, high-value ones, benefits patients, providers, plan sponsors and employer stop-loss carriers alike.